1
|
Kayikci H, Cimen P, Katgi N. Efficiency and Reliability of Bronchoscopic Lung Volume Reduction Coil Application in Patients with Severe Emphysema. Sisli Etfal Hastan Tip Bul 2023; 57:506-512. [PMID: 38268657 PMCID: PMC10805047 DOI: 10.14744/semb.2023.06767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 05/22/2023] [Accepted: 09/07/2023] [Indexed: 01/26/2024]
Abstract
Objectives In the past years, surgery has been used for the non-medical treatment of severe emphysema. However, in recent years, bronchoscopic lung volume reduction (LVR) treatment has become more preferred because it is less invasive. Bronchoscopic coil treatment is the most frequently applied technique among these methods. The aim of the investigation was to determine the efficacy and safety of bronchoscopic volume reduction coil treatment for patients with severe emphysema. Methods The patients who were performed bronchial volume reduction coil treatment between 2015 and 2017 and were followed in our outpatient clinic were retrospectively examined. They were followed for 1 year at quarterly intervals after the procedure. All the safety and efficacy of the patient's records, including the modified Medical Research Council (MRC) dyspnea score, the St. George's Respiratory Questionnaire (SGRQ) quality of life scale, the 6 min walk distance (6-MWT), pulmonary function tests, and adverse events, were evaluated. Results Sixteen patients were included in the study. The mean of the preoperative mMRC clinic dyspnea score was 3.38, the mean of the 3rd month's mMRC score was 2.62 (p=0.007), and the mean of the 12th month's mMRC was 2.37 (p=0.003). The preoperative SGRQ quality of life parameter was 71.95±15.7, the 3rd month was 66.7±16.2 (p=0.007), and the 12th month was 62.9±16.4 (p=0.003). Preoperative mean of 6-MWT was 247.25±112.36 m, 3rd month 264.25±95 m (p=0.148), and 12th month 317±122.9 m (p=0.034). Patients' preoperative residual volume was 5.28±1.96 L, 3rd month 4.52±1.35 L (p=0.023), and 12th month 4.545±1.83 L (p=0.163). Patients' preoperative forced expiratory volume in one second, respectively, was 0.79±0.29 L, 3rd month 0.79±0.3 L (p=0.917), and 12th month 0.86±0.3 L (p=0.756). Conclusion It seems that bronchoscopic LVR coil treatment, which is an effective and reliable procedure that reduces shortness of breath rather than respiratory function test parameters and improves the quality of daily life, will become even more widespread.
Collapse
Affiliation(s)
- Hazal Kayikci
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Türkiye
| | - Pinar Cimen
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Türkiye
| | - Nuran Katgi
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Türkiye
| |
Collapse
|
2
|
Katgi N, Çimen P, Çirak AK, Şimşek T, Ceylan KC, Samancilar Ö, Duman E, Erer OF, Tuksavul FF. Complication and cost analysis of transbronchial lung cryobiopsy and awake video-assisted thoracic surgery in diagnosis of interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2022; 39:e2022005. [PMID: 35494167 PMCID: PMC9007030 DOI: 10.36141/svdld.v39i1.12293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Accepted: 12/17/2021] [Indexed: 12/05/2022]
Abstract
AIM AND INTRODUCTION Diagnosing of interstitial lung disease (ILD) is difficult and expensive. The standard diagnostical approaches to ILD are bronchoalveolar lavage, transbronchial lung biopsy, transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB). SLB is gold standard for the confident diagnosis of ILD but because of the poor performance of the patients it's use is limited. We conducted a retrospective study to point out that TBLC plays an important role in diagnosis of ILD and has fewer complications and lower cost than awake video-assisted thoracic surgery (AVATS). MATERIAL AND METHODS 132 patients who underwent TBLC and AVATS with a pre-diagnosis of ILD in our hospital between 2015 and 2020 were evaluated retrospectively. Diagnosis rates, complications and costs were recorded. RESULTS There were no non-diagnostic materials in 44 patients in AVATS arm. Prolonged air leak was observed in 11(25.0%) of the patients, and six of them (13.6%) were discharged with Heimlich Valve (HV). Median length of stay in the hospital was 8 days, while average patient cost was $515.9 (415.2-2662.9) in the AVATS arm. Non-diagnostic material was obtained from 10 (11.3%) of 88 patients in TBLC arm. Six (6.8%) of them had pneumothorax, only one of them required a chest tube. No patient was discharged with HV (p=0.001). Median cost for each patient with a median hospital stay of 2.0 (1.0-21.0) (p<0.001) days was $171.9 (80.8-1493.3) (p<0.001). DISCUSSION Although TBLC is behind AVATS in terms of diagnostic accuracy, it may be an alternative diagnostic tool in the diagnosis of interstitial lung disease due to its acceptable safety profile and cost-effectiveness.
Collapse
Affiliation(s)
- Nuran Katgi
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| | - Pinar Çimen
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| | - Ali Kadri Çirak
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| | - Tarik Şimşek
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| | - Kenan Can Ceylan
- Department of Thoracic Surgery, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| | - Özgür Samancilar
- Department of Thoracic Surgery, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| | - Elif Duman
- Department of Thoracic Surgery, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| | - Onur Fevzi Erer
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| | - Fatma Fevziye Tuksavul
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
| |
Collapse
|
3
|
Trukhin D, Poddubskaya E, Andric Z, Makharadze T, Bellala RS, Charoentum C, Yañez Ruiz EP, Fulop A, Hyder Ali IA, Syrigos K, Katgi N, Lopez Chuken YA, Rumyana I, Reyes-Igama J, Costamilan RDC, Del Campo García A, Florez A, Paravisini A, Millan S. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). BioDrugs 2021; 35:429-444. [PMID: 33914256 PMCID: PMC8295170 DOI: 10.1007/s40259-021-00483-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/20/2021] [Indexed: 12/29/2022]
Abstract
Background MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin®; EU-bevacizumab). Objectives To confirm clinical similarity between MB02 and EU-bevacizumab, a comparability study was undertaken in the first-line treatment of stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). Patients and Methods This multinational, double-blind, randomized, phase III study (STELLA) compared MB02 or EU-bevacizumab (15 mg/kg) administered with chemotherapy (paclitaxel 200 mg/m2 and carboplatin AUC6) on Day 1 of every 3-week cycle for 6 cycles (Week 18), followed by MB02/EU-bevacizumab in blinded monotherapy until disease progression, unacceptable toxicity, death, withdrawal of consent or end of study (Week 52). The primary efficacy endpoint was objective response rate (ORR) evaluated by an independent radiological review committee (IRC) at Week 18 (intent-to-treat population). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety and immunogenicity. Results A total of 627 subjects were randomized 1:1 to MB02 (n = 315) or EU-bevacizumab (n = 312). ORR, assessed by the IRC at Week 18, was comparable in MB02 (40.3%) and EU-bevacizumab (44.6%) groups. ORR risk ratio of 0.910 (90% CI 0.780 to 1.060; 95% CI 0.758 to 1.092) and ORR risk difference of −4.02 (90% CI −10.51 to 2.47; 95% CI −11.76 to 3.71) were within the similarity predefined margins. There were no significant differences between MB02 and EU-bevacizumab groups in median PFS (36.0 vs 37.3 weeks, respectively; HR 1.187; 95% CI 0.98 to 1.44) and median OS (not achieved; HR 1.108; 95% CI: 0.83 to 1.49) at the end of study. The safety profile of MB02 and EU-bevacizumab regarding nature, frequency and severity of the adverse events (AE) was comparable. The most frequent grade ≥3 investigational-product-related AEs were hypertension and anemia, with a difference between treatment groups of <5%. Anti-drug antibodies (ADA) and neutralizing ADA (NAb) incidence were similar in both treatment groups. Conclusion MB02 demonstrated similar efficacy to EU-bevacizumab, in combination with carboplatin and paclitaxel, in subjects with advanced non-squamous NSCLC, with comparable safety and immunogenicity profiles. Clinical trial registration EudraCT No. 2017-001769-26; ClinicalTrials.gov: NCT03296163.
Collapse
Affiliation(s)
- Dmytro Trukhin
- Day Patient Facility of Dispensary and Policlinic Department, Odessa Regional Oncological Dispensary, Odessa, Ukraine
| | | | - Zoran Andric
- Clinical Hospital Center, Bezanijska kosa Bezanijska kosa bb, Beograd, Serbia
| | | | | | - Chaiyut Charoentum
- Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Muang, Chiang Mai, Thailand
| | - Eduardo P Yañez Ruiz
- Oncology-Hematology Unit. Department of Internal Medicine. School of Medicine, Clinical Research Center SIM, University of the Frontera, Temuco, Chile
| | - Andrea Fulop
- Orszagos Koranyi Pulmonologiai Intezet, VI. Tudobelosztaly, Budapest, Hungary
| | | | - Kostas Syrigos
- Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, Athens, Greece
| | - Nuran Katgi
- Dr. Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, Health Sciences University, Izmir, Yenisehir, Turkey
| | - Yamil Alonso Lopez Chuken
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez" (Centro Universitario contra el Cancer), Monterrey, Nuevo Leon, Mexico
| | - Ilieva Rumyana
- Plovid Department of Medical Oncology, Multiprofile Hospital for Active Treatment Central Onco Hospital OOD, Plovdiv, Bulgaria
| | - Jasmin Reyes-Igama
- Baguio General Hospital and Medical Center. Baguio city, Benguet, Philippines
| | - Rita de Cassia Costamilan
- Fundacao Universidade de Caxias do Sul, Instituto de Pesquisas Clinicas para Estudos Multicentricos, IPCEM, Caxias do Sul, Brazil
| | | | | | | | | | | |
Collapse
|
4
|
Çirak AK, Katgi N, Erer OF, Çimen P, Tuksavul FF, Hakoğlu B. Diagnostic approach in parenchymal lung diseases: transbronchial lung biopsy or cryobiopsy? Turk J Med Sci 2020; 50:1535-1539. [PMID: 32490646 PMCID: PMC7605086 DOI: 10.3906/sag-1910-47] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Accepted: 05/31/2020] [Indexed: 12/12/2022] Open
Abstract
Background/aim Diagnosis of interstitial lung diseases requires a multidisciplinary approach, and a gold standard for histological diagnosis is open lung biopsy. Transbronchial lung biopsy (TBLB) and in recent years an alternative method, cryobiopsy (TBLC), are used for the diagnosis of parenchymal lung lesions. The aim of this study is to compare the efficacy of concomitant conventional TBLB and TBLC. Materials and methods A total of 82 patients who underwent TBLC for diagnosis of diffuse parenchymal lung diseases at Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital between 2015 and 2018 were screened retrospectively and included in the study. Of the patients, 53.7% (n: 44) were male, and 46.4% (n:38) of them were female. The mean age was 58.37 (±9.33) years. First TBLB and then TBLC were performed to all patients in the same session and their diagnostic performances were compared. Results Although both procedures were done in the same session, 45 patients (54.9%) were diagnosed with TBLB and 75 patients (91.5%) were diagnosed with TBLC (P ˂ 0.001). Hemorrhage was observed in 39 patients (47.6%), but only one had a massive hemorrhage. Pneumothorax was observed in 6 patients (7.3%) and none of them required tube drainage. Conclusion Transbronchial lung cryobiopsy is a promising technique for the diagnosis of parenchymal lung diseases compared to transbronchial lung biopsy.
Collapse
Affiliation(s)
- Ali Kadri Çirak
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
| | - Nuran Katgi
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
| | - Onur Fevzi Erer
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
| | - Pinar Çimen
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
| | - Fatma Fevziye Tuksavul
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
| | - Burçin Hakoğlu
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
| |
Collapse
|
5
|
Kayikci H, Cimen P, Katgi N, Ekmekci C. Lung Cancer with Intracardiac Invasion Simulating Sick Sinus Syndrome. Turk Thorac J 2019. [DOI: 10.5152/turkthoracj.2019.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
6
|
Cimen P, Tuksavul FF, Durus H, Ayranci A, Katgi N, Ataman S. Characteristics and Economic Burden of Hospitalized Elderly Patients (≥65) Due to Community-Acquired Pneumonia. Turk Thorac J 2019. [DOI: 10.5152/turkthoracj.2019.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
7
|
Kayikci H, Cimen P, Katgi N, Tuksavul FF. Efficacy and Safety of The Brochial Volum Reduction Treatment For Emphysema. Turk Thorac J 2019. [DOI: 10.5152/turkthoracj.2019.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
8
|
Cirak AK, Katgi N, Erer OF, Cimen P. Diagnostic Approach in Parenchymal Lung Diseases: Transbronchial Lung Biopsy? Cryobiopsy? Turk Thorac J 2019. [DOI: 10.5152/turkthoracj.2019.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
9
|
Tatar E, Tasli F, Alpay H, Korkmaz A, Cayhan VK, Aktar M, Katgi N, Karatas M, Uslu A. Patient with Renal AA Amyloidosis Following Pulmonary Squamous Cell Carcinoma: A Case Report and Literature Review. Turk J Nephrol 2019. [DOI: 10.5152/turkjnephrol.2019.3249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
10
|
Katgi N, Unlu M, Cimen P, Oner E, Serez B, Giakoup D. Pseudomesotheliomatous Primary Squamous Cell Lung Carcinoma: The First Case Reported in Turkey and a Review of the Literature. Open Med (Wars) 2018; 13:324-328. [PMID: 30140749 PMCID: PMC6104199 DOI: 10.1515/med-2018-0049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Accepted: 06/20/2018] [Indexed: 11/15/2022] Open
Abstract
In rare cases, pseudomesotheliomatous tumors spread diffusely within the pleura to form an encasing mass, which may be confused with diffuse malignant mesothelioma (DMM). A 73-year-old male presented with chest pain, dyspnea and a significant loss of weight and appetite. His radiological and clinical features suggested DMM. However, immunohistochemical studies revealed a primary squamous cell cancer of the lung. To the best of our knowledge, this is the first case report of pseudomesotheliomatous primary squamous cell lung cancer in Turkey, and also the seventh case worldwide. The present report aims to present this case, along with a review of the medical literature.
Collapse
Affiliation(s)
- Nuran Katgi
- Department of Pulmonology, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Izmir-Turkey
| | - Mehmet Unlu
- Department of Pulmonology, Luleburgaz State Hospital, Kirklareli-Turkey.,Lüleburgaz Devlet Hastanesi, Göğüs Hastalıkları Kliniği, Lüleburgaz-Kırklareli-Türkiye
| | - Pinar Cimen
- Department of Pulmonology, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Izmir-Turkey
| | - Emre Oner
- Department of Emergency Medicine, Adana State Hospital, Adana-Turkey
| | - Bilkay Serez
- Department of Pulmonology, Trakya University Medical Faculty, Edirne-Turkey
| | - Derya Giakoup
- Department of Pulmonology, Luleburgaz State Hospital, Kirklareli-Turkey
| |
Collapse
|
11
|
Erer OF, Cimen P, Unlu M, Katgi N. Four cases of pulmonary thromboembolism diagnosed by endobronchial ultrasound. J Clin Ultrasound 2017; 45:441-444. [PMID: 27813098 DOI: 10.1002/jcu.22420] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Revised: 09/11/2016] [Accepted: 09/23/2016] [Indexed: 06/06/2023]
Abstract
Endobronchial ultrasound (EBUS) is a technique for the detection of mediastinal abnormalities. A total of 548 EBUS procedures were performed for various indications, and in four cases (0.7%), filling defects in central pulmonary arteries were demonstrated fortuitously during the procedure. Subsequently, all patients underwent contrast-enhanced CT of the thorax to confirm the diagnosis of pulmonary thromboembolism (PTE). In three of the four cases, there was a concomitant lung cancer. PTE can be incidentally detected during EBUS; therefore, pulmonary arteries should be examined carefully during EBUS in all patients, particularly in patients with suspected or proven malignancy. © 2016 Wiley Periodicals, Inc. J Clin Ultrasound 45:441-444, 2017.
Collapse
Affiliation(s)
- Onur Fevzi Erer
- Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Pulmonary Division, Izmir, Turkey
| | - Pinar Cimen
- Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Pulmonary Division, Izmir, Turkey
| | - Mehmet Unlu
- Luleburgaz State Hospital, Pulmonary Division, Kirklareli, Turkey
| | - Nuran Katgi
- Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Pulmonary Division, Izmir, Turkey
| |
Collapse
|
12
|
Abstract
BACKGROUND Exacerbations of COPD are a major component of the socioeconomic burden related to COPD, and frequent exacerbations are associated with greater decline in health status. Tracheobronchial infections are involved in 50-70% of exacerbations, so influenza and pneumococcal vaccines are recommended for prevention. The aim of this study was to determine the level of knowledge among COPD patients about the vaccines, find the rate of patients inoculated with both influenza and pneumococcal vaccines, and assess the effectiveness of vaccination status. METHODS Patients with COPD were recruited from the out-patient clinic of our hospital between September and October 2012. Subject demographic data such as age, gender, level of education, and smoking status were recorded. Vaccination status, number of subjects who were informed by a health-care professional about immunization, and COPD-related emergency or hospital admissions triggered by tracheobronchial infections over 1 y after administration of both influenza and pneumococcal vaccines were noted. RESULTS Eighty-eight subjects were enrolled during the study period. Eighty-two subjects were male (93.2%), 6 subjects were female (6.8%), and the median age was 61.5 y. According to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006 classification, 5 subjects were in stage 1 (5.7%), 22 subjects were in stage 2 (25%), 34 subjects were in stage 3 (38.6%), and 27 subjects were in stage 4 (30.7%). Sixty-two subjects had graduated from primary school (70.5%), 21 subjects had graduated from high school (23.9%), one subject had graduated from university (1.1%), and 4 subjects had no education (4.5%). Forty-five subjects (51%) were vaccinated. There was no significant correlation between level of education and vaccination status (P=.37). Both COPD-related emergency department and hospital visits were significantly decreased in vaccinated patients with COPD (P<.001 and P=.02, respectively). Of all the subjects, 39.7% (35 of 88 subjects) mentioned that no health-care professional recommended vaccination. CONCLUSIONS Physicians should be more aware of vaccination and recommend both influenza and pneumococcal vaccines to all patients with COPD to reduce exacerbations.
Collapse
Affiliation(s)
- Pinar Cimen
- Pulmonary Division, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Yenişehir, Izmir, Turkey
| | - Mehmet Unlu
- Pulmonary Division, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Yenişehir, Izmir, Turkey.
| | - Cenk Kirakli
- Pulmonary Division, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Yenişehir, Izmir, Turkey
| | - Nuran Katgi
- Pulmonary Division, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Yenişehir, Izmir, Turkey
| | - Fatma Demirci Ucsular
- Pulmonary Division, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Yenişehir, Izmir, Turkey
| | - Aysu Ayranci
- Pulmonary Division, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Yenişehir, Izmir, Turkey
| | - Salih Zeki Guclu
- Pulmonary Division, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Yenişehir, Izmir, Turkey
| |
Collapse
|
13
|
Kayaalp İ, Varol Y, Çimen P, Demirci Üçsular F, Katgi N, Ünlü M, Kıraklı C, Güçlü SZ, Ergene O. The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism. Tuberk Toraks 2014. [DOI: 10.5578/tt.7717] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|